- Conditions
- Herpes Simplex Type 2
- Interventions
- HerpV and QS-21, Placebo
- Drug
- Lead sponsor
- Agenus Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 5
- States / cities
- Portland, Oregon • Houston, Texas • Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 4,205
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hip Pain Chronic, Hip Impingement Syndrome, Hip Injuries, Blood Loss, Femoro Acetabular Impingement
- Interventions
- Tranexamic acid, Placebo
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Luspatercept, Placebo
- Drug · Other
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 13
- States / cities
- Stanford, California • New Haven, Connecticut • Tampa, Florida + 10 more
- Conditions
- Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease
- Interventions
- BGC101 (autologous EnEPC preparation), Control medium
- Biological
- Lead sponsor
- BioGenCell Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 3
- States / cities
- San Francisco, California • New Haven, Connecticut • Baltimore, Maryland
- Conditions
- Migraine Headache
- Interventions
- LY2951742, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 37
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 30 more
- Conditions
- Cytomegalovirus (CMV), HIV (Human Immunodeficiency Virus)
- Interventions
- VIR-1388, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Boston, Massachusetts
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- BG00012, Placebo, Glatiramer Acetate
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Huntsville, Alabama + 69 more
- Conditions
- Diabetes Type 2
- Interventions
- Exenatide once weekly suspension, Sitagliptin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 365 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 50 more
- Conditions
- HIV Infections
- Interventions
- VRC01, Placebo for VRC01
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 2,699 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- LY2127399, Placebo Q2W, Placebo Q4W, Methotrexate
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,041 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 75
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 72 more
- Conditions
- Acute Blood Loss Anemia, Fracture
- Interventions
- Iron-Dextran Complex Injection [InFed], Saline Placebo
- Drug · Other
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Osteoarthritis
- Interventions
- Synvisc (Hylan G-F20; hyaluronan injection), Bupivicaine (local anesthesia injection), Kenalog (triamcinolone; corticosteroid injection)
- Drug
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 45 Years to 95 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Arthritis, Rheumatoid
- Interventions
- GSK3196165, Placebo, MTX, Folic (or folinic) acid
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 8
- States / cities
- El Cajon, California • Fort Lauderdale, Florida • Miami, Florida + 5 more
- Conditions
- Chronic Idiopathic Urticaria
- Interventions
- Omalizumab Injection, Xolair Prefilled Syringe
- Drug
- Lead sponsor
- Kashiv BioSciences, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Brandon, Florida • Brooksville, Florida • Miami Lakes, Florida + 1 more
- Conditions
- Heart Failure, Asymptomatic Systolic Dysfunction
- Interventions
- Nesiritide, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Chronic Hepatitis B
- Interventions
- NVR 3-778, Placebo for NVR 3-778, Pegasys
- Drug
- Lead sponsor
- Novira Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 4
- States / cities
- Costa Mesa, California • Pasadena, California • San Diego, California + 1 more
- Conditions
- Sjögrens Disease
- Interventions
- Abiprubart, Placebo
- Drug
- Lead sponsor
- Kiniksa Pharmaceuticals International, plc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 16
- States / cities
- Menifee, California • Poway, California • Whittier, California + 13 more
- Conditions
- Anterior Cruciate Ligament Injuries, Post-traumatic Osteoarthritis, PRP
- Interventions
- platelet rich plasma (PRP) injection, placebo saline injection
- Procedure
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 14 Years to 50 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Obese, Obesity
- Interventions
- HM15275, Placebo of HM15275
- Drug
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 14
- States / cities
- Chula Vista, California • Oak Lawn, Illinois • Ames, Iowa + 10 more
- Conditions
- Asthma
- Interventions
- Dupilumab, Placebo
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 8
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 4 more
- Conditions
- Respiratory Syncytial Viruses, Respiratory Tract Infections
- Interventions
- Ad26.RSV.FA2, Ad35.RSV.FA2, Placebo
- Biological · Drug
- Lead sponsor
- Crucell Holland BV
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Prostatectomy, Pain
- Interventions
- Acetaminophen (Ofirmev), Placebo
- Drug · Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 85 Years · Male only
- Enrollment
- 86 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Psoriatic Arthritis
- Interventions
- Secukinumab 300 mg, Secukinumab 150 mg, Placebo
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • El Cajon, California + 51 more
- Conditions
- Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
- Interventions
- eneboparatide, Placebo
- Combination Product
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 16
- States / cities
- Torrance, California • Denver, Colorado • Chicago, Illinois + 11 more